INTRODUCTION
HIV-1-infected humans occasionally develop antibodies that are capable of broad and potent viral neutralization. Single-cell antibody cloning methods revealed that this serologic activity is due to one or a combination of monoclonal antibodies that target several different epitopes on the HIV-1 spike protein gp160 (Scheid et al., 2009; Walker et al., 2009; West et al., 2014; Wu et al., 2010) . When passively transferred into humanized mice or macaques, bNAbs protect against infection for prolonged periods of time (Gautam et al., 2016; Klein et al., 2012; Mascola et al., 2000; Moldt et al., 2012; Shibata et al., 1999; Shingai et al., 2013 ) Therefore, it is generally accepted that a vaccine that elicits such antibodies would be protective (Pantaleo and Koup, 2004) . However, after more than 25 years and innumerable pre-clinical studies and human vaccine trials, bNAbs have not been elicited by immunization (Burton et al., 2004; Cohen and Dolin, 2013; Schiffner et al., 2013) .
In addition to uncovering new sites of vulnerability on the HIV-1 spike, antibody cloning revealed several unusual features of anti-HIV-1 antibodies. These include long complementarity determining region 3 s (CDR3s), a higher than expected propensity to polyreactivity, and an unusually high level of somatic hypermutation (SHM) (Dimitrov, 2010; Kwong et al., 2013; Mascola and Haynes, 2013; Scheid et al., 2009; West et al., 2014) . Irrespective of their targets on the HIV-1 spike, the high level of somatic hypermutation is the most conserved among these unusual features of bNAbs. Moreover, mutation is essential for bNAb activity (Bonsignori et al., 2011; Klein et al., 2013a; Mouquet et al., 2012 Mouquet et al., , 2010 Scheid et al., 2011; Sok et al., 2013; Zhou et al., 2010) and within longitudinal antibody lineages, the level of somatic mutation is directly correlated with antibody activity (Bhiman et al., 2015; Doria-Rose et al., 2014; Klein et al., 2013a; Liao et al., 2013; Sok et al., 2013; Wu et al., 2011 Wu et al., , 2015 .
Hypermutation occurs in germinal centers where B-lymphocytes undergo clonal expansion and affinity-based selection in response to antigen (Victora and Nussenzweig, 2012) . Under normal circumstances, the germinal center reaction is limited by antigen availability and by an antibody affinity ceiling (Baumjohann et al., 2013; Foote and Eisen, 1995; Goodnow et al., 2010) . However, longitudinal studies of HIV-1 antibody evolution have shown that HIV-1 can escape immune pressure by mutation and selection, resulting in a continually evolving antigen that produces a persistent immune response to a highly variable infection (Bhiman et al., 2015; Doria-Rose et al., 2014; Kwong et al., 2002; Liao et al., 2013; Stewart-Jones et al., 2016) . Consistent with this notion, prospective studies of HIV-1-infected humans that develop bNAbs revealed interdependence between changes in viral and the antibody sequences (Bhiman et al., 2015; Doria-Rose et al., 2014; Liao et al., 2013; Richman et al., 2003; Wei et al., 2003) . Thus, as initially proposed (Scheid et al., 2009) , the high levels of somatic mutation found in bNAbs are most consistent with continuing parallel evolution of the virus and the antibody response (Klein et al., 2013a (Klein et al., , 2013b Mouquet et al., 2010 Mouquet et al., , 2012 Scheid et al., 2009 ).
PGT121 and related antibodies target a region of the HIV-1 spike that is heavily glycosylated (Kong et al., 2013) . Their target epitopes comprise the GlyAspIleArg (GDIR) sequence at the base of the V3 loop and surrounding glycans at positions Asn332, Asn156, Asn301, and Asn137 (N332, N156, N301, N137) (Garces et al., 2014 (Garces et al., , 2015 Julien et al., 2013; Mouquet et al., 2012; Sok et al., 2014; Walker et al., 2009 Walker et al., , 2011 . These antibodies are commonly found in individuals that develop bNAbs during natural infection Walker et al., 2010 Walker et al., , 2011 . In addition, they are also among the most potent bNAbs discovered to date (Kwong et al., 2013) .
PGT121 antibodies show high levels of somatic mutations and arise from a singular precursor that diverges into two distinct families, exemplified by PGT121 (Walker et al., 2011 ) and 10-1074 or PGT124 Sok et al., 2013) . Somatic mutations differentiate the PGT121 lineage that recognizes glycans at N301, N137, and N156 from the 10-1074 or PGT124 lineage that is highly dependent on N332 but less so on the other glycans surrounding the base of the V3 loop (Garces et al., 2014 (Garces et al., , 2015 Mouquet et al., 2012; Sok et al., 2013 Sok et al., , 2014 . Finally, like other bNAbs, the inferred germline precursor of PGT121 antibodies shows no appreciable affinity for all HIV-1 Env antigens tested and no neutralizing activity (Andrabi et al., 2015; DoriaRose et al., 2014; Gorman et al., 2016; Klein et al., 2013a; Liao et al., 2013; Mouquet et al., 2012; Sok et al., 2013) .
Based on the requirements for unusually high levels of somatic mutation in bNAbs, and the inability of germline reverted antibodies to bind to native-like antigens, it was proposed that a vaccine to elicit these antibodies would necessitate a new paradigm involving a germline prime followed by sequential immunization with different antigens (Dimitrov, 2010; Haynes et al., 2012; Jardine et al., 2013; Klein et al., 2013a Klein et al., , 2013b Mouquet et al., 2012; Pancera et al., 2010; Scheid et al., 2009 Scheid et al., , 2011 Zhou et al., 2010) . To test this idea, we have sequentially immunized mice that carry the germline reverted version of the PGT121 family precursor with a series of specifically engineered antigens (Steichen et al., 2016) .
RESULTS

PGT121 Mice
Mice carrying the immunoglobulin (Ig) V(D)Js encoding the inferred germline or fully mature heavy chain, and the predicted germline light chain of PGT121 (GL H 121, Mut H 121, and GL L 121, respectively) were produced by gene targeting Albino B6 (B6 (Cg)-Tyrc-2J/J) embryonic stem cells ( Figure S1A ) (Pelanda et al., 1997; Shih et al., 2002) . The GL121 sequence contains germline V, D, and J genes, and the naturally occurring CDRH3 sequence corresponding to the least mutated antibodies in this lineage (Kepler, 2013; Mouquet et al., 2012 (Dosenovic et al., 2015; von Boehmer et al., 2016) . In both genotypes, the antibodies were composed exclusively of products of the knockin antibody genes ( Figure S1D ). We conclude that the majority of the B cells in GL HL 121 and Mut H GL L 121 mice express the respective knockin gene and develop normally.
Activation of GL HL 121 B Cells In Vivo
Germline reverted PGT121 does not bind to native-like Env antigens and shows no neutralizing activity for all HIV-1 isolates tested (Klein et al., 2013a; Mouquet et al., 2012; Sok et al., 2013) . Consistent with this observation, the serum of naive GL HL 121 and Mut H GL L 121 mice did not bind to the native-like Env protein BG505 SOSIP in ELISA ( Figures S2A and S2B) . Moreover, repeated immunization with native-like Env proteins YU2 SOSIP, BG505 SOSIP, or other Env-based immunogens such as BG505-5MUT and BG505-3MUT (5 and 3MUT, respectively; Steichen et al., 2016) failed to elicit antibody responses in GL HL 121 mice (Figures S2A and S2B) . These results are in agreement with the observation that native-like Env immunogens failed to induce immune responses in knockin mice that carry the inferred germline heavy chains of 3BNC60 or VRC01, and with the idea that activating germline bNAb-expressing B cells requires specifically engineered antigens (Dosenovic et al., 2015; Hoot et al., 2013; Jardine et al., 2013 Jardine et al., , 2015 Jardine et al., , 2016 Mouquet et al., 2010; Scheid et al., 2009; Xiao et al., 2009) .
To attempt to activate B cells that carry PGT121 antibody precursors, we immunized GL HL 121 and Mut H GL L 121 mice with BG505-10MUT (10MUT), a BG505 variant that was specifically engineered to bind to germline reverted PGT121 antibodies (Steichen et al., 2016 ). 10MUT binds to Mut H GL L with a K d = 47,000 nM, whereas it has no measurable affinity to GL HL 121 ( Figure S2C ) by surface plasmon resonance. Despite the lack of measurable affinity to GL HL 121, a single immunization with 10MUT trimer, but not the corresponding monomer, elicited antibody responses in both GL HL 121 and Mut H GL L 121 mice as measured by ELISA ( Figure 1A) . Moreover, the antibodies induced by immunization of both types of mice specifically targeted the PGT121 epitope on Env, because binding to 10MUT was eliminated by mutation at positions N332, N301, and H330A (10MUT knockout [KO] ) (Figures 1A and 1B) . Despite the specificity of the response, immunization with 10MUT did not elicit neutralizing activity (Figure S2D (A) ELISAs against 10MUT gp120 and a mutated version of the same protein that is missing the PGT121 epitope (10MUT gp120 KO) using serum (1:100 starting dilution) from GL HL 121 and Mut H GL L 121 mice primed with monomeric 10MUT (10MUT gp120, left) or trimeric 10MUT (10MUT SOSIP, right). (B) ELISA using human PGT121 (5 mg/ml) against 10MUT gp120 and 10MUT gp120 KO. (C) Diagram shows the sequential immunization protocol delivered over a period of 5-6 months. (D) ELISAs of serum from a control and a representative sequentially immunized GL HL 121 mouse after immunization steps 1-4. Test proteins are indicated above each column. ELISAs are ordered from left to right according to level of capture antigen modification compared to wtBG505. When indicated, the specificity of the serologic response for the PGT121 epitope was also evaluated by ELISA against the 10MUT gp120 KO protein. Each row of ELISA graphs represents the indicated step in the immunization protocol. A model of the corresponding immunogen is shown below each row (Steichen et al., 2016) . Blue spheres represent glycans and red spheres indicate mutated residues. Heavy chain (H1-3) and light chain (L1-3) loops are represented in the model of wtBG505. Red asterisks indicate the boosting immunogens. VLC = five native-like SOSIPs differing in the variable loops (Steichen et al., 2016) . See also Figure S1 and S2.
10MUT and native-like antigens and showed varying affinities (1-10 nM) for the mature PGT121 antibody ( Figures 1C and 1D ) (Steichen et al., 2016) . ELISA testing of mouse serum on these proteins after each immunization, and consideration of the directionality engineered into the immunogens, determined the sequence of boosting immunogens ( Figures 1C and 1D ). For example, we selected 7MUT for boosting after immunization with 10MUT because 7MUT was the least mutated immunogen that showed detectable binding to the serum of the immunized mice by ELISA ( Figure 1D ; data not shown). Subsequent immunogens were selected in the same manner ( Figure 1D ).
Longitudinal ELISA testing of the serum from sequentially immunized mice revealed that antibody responses were boosted in response to each of the immunogens while remaining specific for the PGT121 epitope ( Figures 1D, 2A , 2B, S2E, and S2F; data not shown). After immunization with 5MUT, the serum of one GL HL 121 and all seven Mut H GL L 121 mice showed binding to BG505 SOSIP in ELISAs ( Figure 2B ; data not shown), and, though serum reactivity to 3MUT and 2MUT was also detected, immunization with either of those proteins at this stage would have violated directionality because both lack native PGT121-epitope glycans that are present in 5MUT and BG505 SOSIP (Steichen et al., 2016) . Thus, the BG505 SOSIP was used as a boost after 5MUT and then followed by a cocktail of five native-like SOSIPs differing in their variable loops (variable loop cocktail [VLC] ) (Steichen et al., 2016) . After the final immunization, all but one of the GL HL 121 and all of the Mut H GL L 121 mice showed binding to the five native-like VLCs ( Figure 2B ; data not shown).
Broadly Neutralizing Antibodies
To determine whether sequential immunization elicited anti-HIV-1 bNAbs, purified serum antibodies from control, and immunized mice, were tested for neutralizing activity by TZM-bl assay using a panel of 12 tier 2 and two tier 1B viruses (Figure 3A) . Igs from naive control mice showed no neutralizing activity. In contrast, five of seven GL HL 121 and all seven of the Mut H GL L 121 mice showed cross-clade neutralization against heterologous tier 2 isolates ( Figure 3A ). As expected, none of the purified serum Igs samples neutralized HIV-1 R1166 , which lacks the N332 N-linked glycosylation site that is critical for the binding and in vivo activity of PGT121 antibodies ( Figure 3A ) (Klein et al., 2012 (Klein et al., , 2013a Mouquet et al., 2012; Walker et al., 2011) .
To further evaluate the breadth of the serologic responses, purified Ig from one GL HL 121 and one Mut H GL L 121 mouse was assayed against a panel of 54 tier 2 and two tier 1B viruses. Whereas PGT121 neutralized 50 of these isolates, GL HL 121 and Mut H GL L 121 Igs neutralized 12 and 23 tier 2 HIV-1 isolates, respectively ( Figure S3 ). Thus, the serum Igs isolated from sequentially immunized mice showed strong cross-clade tier-2-neutralizing activity, but less breadth than PGT121.
To determine when neutralization activity emerged, we assayed intermediate time points in the sequential immunization series. In both GL HL 121 and Mut H GL L 121 mice, neutralization was first detected after immunization with 5MUT ( Figure 3B ). However, this activity was less broad and less potent than that found after the complete immunization series ( Figures 3A and 3B) .
To determine whether repeated doses of a single antigen or a simplified protocol can also elicit bNAbs, we immunized repeatedly with the priming antigen 10MUT, or alternatively with 10MUT followed by BG505 separated by a period of time equivalent to the original sequential protocol. Analysis of the serum from the GL HL 121 mice by ELISA showed no significant binding to native-like Env proteins ( Figures S4A and S4B ). Repeated immunization with 10MUT elicited some weak neutralization activity in three of six Mut H GL L 121 mice and little or no detectable activity in any of the GL HL 121 mice ( Figure 3C ). Similarly, 10MUT followed by BG5050 was entirely ineffective in GL HL 121 mice and produced only weak neutralizing activity in one of three Mut H GL L 121 mice ( Figure 3D ). We conclude that repeated immunizations with 10MUT or the combination of 10MUT and BG505 in absence of intermediate antigens is far less effective than sequential immunization with different antigens.
To determine whether an abbreviated immunization protocol using some of the same antigens would also elicit bNAbs, we primed with 7MUT and boosted with 5MUT, followed by wtBG505 and VLCs ( Figure S4C ). Analysis of the serum by ELISA revealed that this protocol was less effective in eliciting antibodies with binding affinity to native-like Env proteins (Figure S4C) . Consistent with the ELISA data, the abbreviated protocol produced less potent neutralizing activity, and in only one of three GL HL 121 and the three Mut H GL L 121 mice ( Figure S4D ). Similarly, priming with 11MUT A , a higher affinity variant of 10MUT followed by 5MUT, wtBG505, and VLCs elicited only weak ELISA activity against native-like proteins and low levels of neutralizing antibodies in Mut H GL L 121 and none in GL HL 121 mice (Figures S4E and S4F) .
We conclude that sequential immunization guided by ELISA measurements is effective in inducing maturation of PGT121 germline antibodies to become bNAbs in Ig knockin mice.
Antibody Sequences from Sequentially Immunized Mice
To characterize the antibodies elicited by sequential immunization, we cloned them from purified single IgG + memory B cells binding to a mixture of three different gp120 proteins but not to mutants of these proteins that do not bind to PGT121. Sequential immunization with a series of related antigens induced remarkably high levels of somatic mutation in the IGK of the knockin mice, reaching a maximum of 34 and 25 nucleotide, or 21 and 18 amino acid mutations in GL HL 121 and Mut H GL L 121 B cells, respectively (Figures 4A, 4B, and 4D; Figures S5A, S5B, and S5D) . In contrast, high levels of IGH mutation were found only in GL HL 121 and not in pre-mutated 121 IGH in Mut H GL L 121 mice (Figures 4C and 4E; Figures S5C and S5E) . Thus, although the somatic mutation machinery was similarly active in the germinal center B cells of both knockin mice, the Mut H 121 was less susceptible to additional mutation, possibly because some of the target sequences for activation induced cytidine deaminase (AID) had already been mutated ( Figure S5F ) (Dosenovic et al., 2015; Pavri and Nussenzweig, 2011) . Finally, despite the high level of mutation, we found no deletions or insertions in the IGH or IGK of either of the immunized mice (Kepler et al., 2014) .
To determine whether induction of high levels of mutation requires sequential immunization, we isolated single antigen-specific IgG + memory B cells from mice immunized repeatedly with 10MUT or 10MUT followed by wtBG505. Multiple immunizations with 10MUT, or 10MUT followed by BG505 induced significantly lower levels of SHM at both the nucleotide and amino acid levels in GL HL 121 and Mut H GL L 121 B cells than the sequential protocol (Figures 5A-5F; Figures S5G-S5I). We conclude that repeated immunizations with one or two antigens fails to elicit the high levels of mutation found after sequential immunization.
Neutralization by Monoclonal Antibodies
Antibodies from immunized mice showed somatic mutations that were in some cases identical or similar to mutations in PGT121, PGT122, PGT123, or 10-1074 (PGT121-like). Indeed, there was a direct correlation between the total number of amino Figure S6 and S7). Among the 40 and 37 antibodies cloned from GL HL 121 and Mut H GL L 121 mice, 15 and 17, respectively, showed neutralizing activity against tier 2 HIV-1 isolates including antibodies Ab6 and Ab8 that were cloned from GL HL 121 mouse M7 that had no detectable neutralizing activity in serum (Figures 3A and 6C) . In contrast, none of the antibodies cloned from mice repeatedly immunized with 10MUT showed any neutralizing activity in TZM-bl assays (Figures 6 and S6) . Thus, the activity of the monoclonals generally reflected the neutralizing activity found in serum. However, bNAbs were also obtained from immunized mice with no detectable serologic activity (Figures 3 and 6) .
Among the monoclonal antibodies tested, there was significant variation in neutralizing breadth and potency. As expected, the neutralizing activity of the monoclonal antibodies was directly related to their ability to bind to the native-like BG505 SOSIP protein in ELISA (Figures S6A and S6B) (Sanders et al., 2013) . For example, antibodies Ab1, Ab2, and Ab3 showed high level binding in ELISA and neutralized ten viral strains whereas antibodies Ab18 and Ab19 did not bind to BG505 and did not neutralize any of the strains in the panel (Figures 6 and  S6B) . However, the potency of the autologous response to the BG505 T332N pseudovirus was unexpectedly low. Although additional analysis of these responses is required, the results suggest some structural differences between the epitopes on the immunogen and the pseudovirus.
Neutralizing activity was directly related to the number of somatic mutations (r 2 = 0.708) (Figure 6A) . A direct correlation between the number of mutations and the number of PGT121-like mutations was also observed when all the amplified heavy-chain and light-chain sequences from all the mice immunized with the different protocols were analyzed (r 2 = 0.902 for heavy chains; r 2 = 0.864 for light chains) (Figure 6B ). The antibodies with the best neutralizing activity carried amino acid substitutions at positions in IGH that make a critical contribution to Env binding; for example, S56N contributes to the interaction with the N137 glycan and D100iE resides near the GDIR motif (Garces et al., 2014; Sok et al., 2013) . Moreover, CDRH3 residues found in the inferred germline that are also present in the mature PGT121 and involved in antigen-antibody interactions were retained (R103 and Y105, which make contacts with N332 glycan and the GDIR motif, respectively). Similarly, the IGK in the neutralizing monoclonals showed amino acid substitutions at positions that contribute to the neutralizing activity of PGT121 (N25D, H33P, D50N [N332 glycan contact] and the S92, S93, S94 [GDIR recognition]) Sok et al., 2013) (Figures 7A and 7B ). In addition, although none of the monoclonals carried the insertion in FWRL3 found in PGT121, the most potent antibodies had several amino acid mutations surrounding this region that may represent an alternative mechanism to enhance activity (Figure 7B) .
We conclude that sequential immunization induces maturation of the predicted germline PGT121 antibody in a manner that in part recapitulates the maturation of the authentic monoclonal obtained from an HIV-1-infected individual.
DISCUSSION
Antibodies hold great promise for HIV-1 prophylaxis because they can prevent infection in pre-clinical models even at low concentrations (Gautam et al., 2016; Gruell et al., 2013; Klein et al., 2012; Mascola et al., 2000; Moldt et al., 2012; Shibata et al., 1999; Shingai et al., 2013) . Moreover, broad and potent antibodies to HIV-1 develop in a fraction of infected individuals suggesting that such antibodies might also be elicited by vaccination (Burton and Hangartner, 2016; Haynes and Montefiori, 2006; Hraber et al., 2014; Klein et al., 2013b; Mascola and Haynes, 2013; McCoy and Weiss, 2013; West et al., 2014) . However, despite over 25 years and a very significant effort by numerous investigators, bNAbs have not been elicited by vaccination, and a preventative vaccine against HIV-1 has yet to be developed.
There are several reasons why bNAbs may be difficult to elicit. First and foremost, is that all the bNAbs isolated to date show unusually high levels of somatic mutation that are required for their activity (Klein et al., 2013a (Klein et al., , 2013b Mascola and Haynes, 2013; Mouquet et al., 2010 Mouquet et al., , 2012 West et al., 2014) . Hypermutation is a random process that introduces one nucleotide change per 10 3 bp per cell division in B cells dividing in the dark zone of the germinal center (Victora and Nussenzweig, 2012) . B cell residence in germinal centers and selection by affinity are limited for any given antigen (Victora and Nussenzweig, 2012) . Therefore, acquisition of the right combination of mutations to produce a bNAb is highly unlikely to occur by immunization with a monomorphic antigen. Based on these considerations, we and others proposed that sequential immunization would be required for bNAb development (Dimitrov, 2010; Haynes et al., 2012; Jardine et al., 2013; Klein et al., 2013a Klein et al., , 2013b Pancera et al., 2010; Scheid et al., 2009 Scheid et al., , 2011 Zhou et al., 2010 ). This idea is strongly supported by data obtained from prospective studies of infected humans that showed that bNAbs develop in response to sequentially evolving variants of HIV-1, which are, in turn, selected by the developing antibodies (Bhiman et al., 2015; Doria-Rose et al., 2014; Liao et al., 2013; Wu et al., 2011 Wu et al., , 2015 .
An additional impediment to immunization to elicit broadly neutralizing responses is that few of the predicted germline precursors of bNAbs bind to native-like antigens (Doria-Rose et al., 2014; Hoot et al., 2013; Klein et al., 2013a; Liao et al., 2013; Mouquet et al., 2010 Mouquet et al., , 2012 Scheid et al., 2011; Xiao et al., 2009) . Consistent with these observations, specifically engineered Env-based immunogens or naturally occurring germline-binding Env (Andrabi et al., 2015; Doria-Rose et al., 2014; Gorman et al., 2016; Liao et al., 2013) appear to be necessary to initiate immune responses by B cells that express the germline precursors of CD4bs bNAbs (Dosenovic et al., 2015; Jardine et al., 2013 Jardine et al., , 2015 did not elicit neutralizing responses in mice that carry the germline precursors of CD4bs antibodies (Dosenovic et al., 2015; Jardine et al., 2015) . Only a native-like antigen activated B cells expressing a synthetic intermediate antibody to produce tier-2-neutralizing antibodies (Dosenovic et al., 2015) . These results provided the initial direct experimental support for the notion that a succession of different immunogens would be necessary to drive bNAb maturation (Dosenovic et al., 2015) . Extension of these results to humans might be achieved by immunizing individuals that have modest levels of serologic activity with native-like antigens to see whether this would increase potency and breadth (Schoofs et al., 2016) .
Previous experiments with HIV-1 antigens in mice, rabbits, and macaques showed some increase in the breadth and potency of the response to tier 1 viruses by sequential immunization. However, those experiments did not produce serologic responses or antibodies with broad neutralizing activity against tier 2 strains, nor were somatic mutations analyzed (Eda et al., 2006; Klinman et al., 1991; Malherbe et al., 2011) . In addition, immunization with singular native-like envelope trimers elicits antibodies that neutralize the autologous virus but not heterologous strains (Sanders et al., 2015) . None of those studies involved germlinetargeting immunogens to prime bnAb precursors specifically. Our experiments demonstrate that immunization with a germline-targeting prime followed by ELISA-guided boosting with a sequence of directional immunogens designed to be progressively more native-like, with decreasing binding affinities to the inferred germline PGT121/10-1074 bNAb, induces high levels of somatic hypermutation. Similar to humans that develop bNAbs, the level of somatic mutation in knockin mice was directly related to the acquisition of neutralizing activity. Finding that priming with a germline-targeting immunogen followed by a sequence of boosting immunogens partially reproduces the development of PGT121 antibodies in knockin mice represents (legend continued on next page) proof of concept for the idea that sequential immunization can elicit bNAbs. The sequential boosting protocols that succeeded to elicit bNAbs and high levels of SHM were those in which the epitope structure changed gradually with each successive boost. In contrast, the protocols that failed to elicit bNAbs involved large changes in the epitope in at least one boost, such as 10MUT followed by BG505 (Figure S4B ), or 11MUT A followed by 5MUT ( Figure S4F ). We have proposed that affinities of boosting immunogens for an intermediate mAb can be used to guide design of boosting protocols, that large affinity changes between successive immunogens corresponds to large changes in epitope structure, and that boosting protocols avoiding large affinity drops are more likely to succeed (Steichen et al., 2016) . The observation that gradual protocols succeed here provides experimental evidence in support of that affinity-drop analysis. This could allow future studies to prioritize experimental testing of sequential schemes (and optimize those schemes) based on similar affinity-drop analyses.
Antibodies that target the glycan patch, including PGT121, are frequently found in infected individuals that develop bNAbs (Kong et al., 2013; Mouquet et al., 2012; Walker et al., 2011) . These antibodies are highly mutated, but less so than some others in the VRC01 class of bNAbs, and are therefore particularly attractive targets for vaccine development Mouquet et al., 2012; Scheid et al., 2009 Scheid et al., , 2011 Walker et al., 2009 Walker et al., , 2011 Wu et al., 2011; Zhou et al., 2010) . Moreover, analysis of predicted intermediates in the PGT121 lineage showed that even antibodies with lower levels of mutation than PGT121, such as 3H+3L, have significant breadth and potency . Similarly, an antibody targeting the N332 supersite, BF520.1, showing relatively low levels of mutation was recently isolated from an infected infant (Simonich et al., 2016) . However, this antibody is over 100 times less potent than PGT121. The antibodies that develop in GL HL 121 knockin mice appear to be far more potent than BF520.1 and closely resemble PGT121 intermediates.
The antibody responses elicited by our immunization scheme are suboptimal because they do not reach the full activity of PGT121. Additional variables should be tested to further increase the potency and breadth of these antibody responses. These include the use of alternative adjuvants (Stills, 2005) , timing between boosting, and immunogen dose (Gonzá lez-Ferná ndez and Milstein, 1998). Moreover, interspecies differences in the Ig repertoire, B cell development, and FcR or Toll-like receptor expression should also be considered (Mestas and Hughes, 2004) . Most importantly, our experiments are limited to knockin mice and cannot be immediately translated to organisms such as humans with a diverse immune system where the germline precursor B cell frequency is limited. Additional immunogens with increased affinities for the predicted germline forms of bNAbs will likely be required to activate the rare bNAb precursors found in the normal naive B cell repertoire.
Despite these important caveats, our experiments establish the principle that a vaccination strategy based on sequential immunization with specifically engineered immunogens induces B cells expressing predicted germline precursors to develop bNAbs.
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METHODS DETAILS
Immunogens Engineered Env proteins used as immunogens (11MUT A , 10MUT, 7MUT, 5MUT, 3MUT, BG505 (VLC2), VLC1, VLC3, VLC4 and VLC5 SOSIPs and 10MUT gp120) are described in (Steichen et al., 2016) . The BG505-SOSIP.664 variants, which included the T332N mutation from the native BG505 HIV Env sequence, 3MUT: T135A and T139I; 5MUT: V134Y, N136P, I138L, D140N; 6MUT: 5MUT+ T139I; 7MUT: 6MUT+ T135A; 9MUT A : 7MUT+ N137F+ Q328M; 9MUT B : 7MUT+ T135R+ Q328M; 10MUT: 7MUT+ N137F+ T320F+ Q328M; 11MUT A : 10MUT+ D141N. The 10MUT gp120 also contained the L111A mutation. VLC (variable loop cocktail) contains 5 native-like SOSIPs differing in the variable loops (Steichen et al., 2016) . Monomeric Env gp120s (11MUT A, 10MUT, 10MUT KO, 9MUT A, 9MUT B, 7MUT, 6MUT, 5MUT, 3MUT, 2MUT), which included L111A, and HIS tagged SOSIPs (BG505, VLCs) were used for ELISAs. AviTag-biotinylated Env gp120 proteins 10MUT, 5MUT, P1981_c5_3, CAAN5342.A2 and corresponding PGT121 epitope ELISA ELISA to the monomeric gp120 versions of 11MUT A ,10MUT, 10MUT KO, 9 MUT B , 9MUT A , 7MUT, 6MUT, 5MUT, 3MUT and 2MUT were performed by coating of high bind 96 well plates (Corning #9018) with 100ml per well of a 2mg/ml protein solution in PBS overnight at 4 C. Plates were washed 6 times with washing buffer (1xPBS with 0.05% Tween 20 (Sigma-Aldrich)) and incubated in blocking buffer (1xPBS with 1% Milk) for 1 hr (h) at room temperature (RT). Immediately after blocking, monoclonal antibodies or serum samples were added in blocking buffer and incubated for 2 hr at RT. Serum samples were assayed at a 1:100 starting dilution and seven additional 3-fold serial dilutions. Monoclonal antibodies were tested at 5 or 10mg/ml as specified in the Results section. Plates were washed 6 times with washing buffer and then incubated with anti-mouse or anti human IgG secondary antibody conjugated to horseradish peroxidase (HRP) (Jackson Laboratories) in washing buffer at a 1:5000 dilution. Plates were developed by addition of the HRP substrate, ABTS (Life Technologies) and absorbance was measured at 405nm with an ELISA microplate reader (FluoStar Omega, BMG Labtech). Alternatively, for ELISA to the wtBG505 SOSIP and VLC SOSIP, plates were pre coated with an anti-6X His tag antibody (Abcam) in 1xPBS overnight at 4 C. After overnight incubation, plates were washed six times and blocked for 1 hr at RT using the same buffers as specified above. Immediately after blocking, the His tagged wtBG505 SOSIP and VLC SOSIP proteins were added at 2mg/ml in dilution buffer (1xPBS with 1% fetal bovine serum and 0.2% Tween20) to all the wells and incubated at RT for 1 hr. Plates were then washed six times and blocked for 1 hr at RT. Serum Ig or monoclonal antibodies were added in dilution buffer at the dilutions previously mentioned and incubated for 2 hr at 37 C. Plates were then washed six times and incubated with secondary antibody for 1.5 hr at 37 C. Finally plates were developed and measured as specified above. Neutralization Assay TZM-bl assays were performed as described (Montefiori, 2005) . In brief, neutralization activity was calculated as a function of the reduction in Tat-induced luciferase expression in the TZM-bl reporter cell line after a single round of virus infection.
Ig Purification
A total neutralization score was obtained by a sum of the individual scores assigned as (IC 50 < 0.01 score 4; 0.01-0.1 score 3; 0.1-1 score 2; > 1 score 1; not detectable (ND) score 0) normalized by the number of viruses tested in the TZM-bl assay.
Flow Cytometry
Cells from spleens were stained with cocktails of the following anti-mouse antibodies: anti-CD4 APC-eFluor 780, anti-CD8 APCeFluor 780, anti-Ly-6G (Gr1) APC-eFluor 780, anti-F4/80 APC-eFluor 780, anti-B220 FITC, anti-CD38 Alexa Fluor 700, anti-IgM PerCP-eFluor 710, anti-CD21/CD35 eFluor 450 and anti-IgG1 BV421 (BD Biosciences); anti-CD23 PE (BioLegend); anti IgD PE/ Cy7 and anti Ig light chain l (Biolegend). Dead cells were excluded by staining with the Live-dead aqua stain (Life Technologies). Stained cell samples were analyzed in a BD LSR Fortessa analyzer. Single cells were sorted into individual wells of a 96-well plate containing 4ml of lysis buffer (RNASin (Promega) 40 U/ml (0,3 ml), 10xPBS (Dulbecco) (0.2 ml), DTT (Invitrogen) 100 mM (0.4 ml) and nuclease-free water (3.1 ml)) using a FACS Aria III (Becton Dickinson). Plates were immediately frozen on dry ice and stored at À80 C or processed for cDNA synthesis. cDNA from single cells was obtained by reverse transcription (Superscript III, Invitrogen) and used for amplification by nested PCR using the sequencing or cloning primers listed in (Figure S7 ) (von Boehmer et al., 2016 
Antibody Cloning and Production
Amplified heavy chain and light chain cDNAs were individually cloned into expression vectors containing the corresponding mouse antibody constant regions by using the sequence and ligation-independent cloning (SLIC) methodology (Li and Elledge, 2007; von Boehmer et al., 2016) . DNA sequences that are complementary to the destination vector were added to the amplified IGH and IGK cDNAs by PCR using the cloning primers listed in (Figure S7 ). PCR protocol (annealing ( C)/ elongation (sec)/ number of cycles): 68/ 55/50. Amplified cDNA was purified with QIAquick 96 PCR Purification Kit following manufacturer instructions. The linearized vector (30-50ng) and the insert (4 ml of purified product) were ligated at 25 C for 2.5 min. Ligation was either stored at 4 C or transformed in DH5a competent bacteria. Next day, bacterial colonies were analyzed by PCR using the primers indicated in Figure S7 . PCR protocol (annealing ( C)/ elongation (sec)/ number of cycles): 57/55/35. Antibodies were produced by transient transfection of HEK293T cells with equal amounts of immunoglobulin heavy and light chain expression vectors. After 7 days, the supernatant was harvested and antibodies were concentrated by ammonium sulfate precipitation. IgG was purified with Protein G-Sepharose 4 Fast Flow .
Analysis Software Geneious 9.0.4 and MacVector 14.0.3 were used for sequence analysis and graphs were created using R language. Flow cytometry data were processed using FlowJo 10.0.7. GraphPad Prism 6.0f was used for data analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical information including n, mean and statistical significance values are indicated in the text or the figure legends. GraphPad Prism 6.0f was used to calculate Pearson correlation coefficients and for statistical analysis by one-way ANOVA and Tukey multi comparison test or unpaired T-Test. Data were considered statistically significant at *p % 0.05, **p % 0.01, ***p % 0.001 and ****p % 0.0001. 
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